Cocrystal Pharma (COCP) EBITDA (2010 - 2026)

Cocrystal Pharma (COCP) has 17 years of EBITDA data on file, last reported at -$2.4 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 0.64% year-over-year to -$2.4 million; the trailing twelve-month figure through Mar 2026 stood at -$9.0 million (up 43.75% YoY), and the FY2025 full-year result was -$9.0 million, up 49.55% from the prior year.
• EBITDA grew to -$2.4 million in Q1 2026, from -$2.5 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$2.1 million in Q3 2025 to a low of -$24.4 million in Q2 2022.
• A 5-year average of -$5.1 million and a median of -$4.3 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA sank 538.14% in 2022 and jumped 82.24% in 2023, its largest moves.
• Tracing COCP's EBITDA over 5 years: stood at -$4.5 million in 2022, then declined by 3.64% to -$4.7 million in 2023, then surged by 30.78% to -$3.2 million in 2024, then gained by 23.19% to -$2.5 million in 2025, then grew by 5.04% to -$2.4 million in 2026.
• Business Quant data shows COCP's EBITDA at -$2.4 million in Q1 2026, -$2.5 million in Q4 2025, and -$2.1 million in Q3 2025.